




RealRate

PHARMACEUTICAL 2021

Homology Medicines Inc.
Rank 239 of 409

HOMOMLOGY
Medicines, Inc.



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Homology Medicines Inc.
Rank 239 of 409



The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Homology Medicines Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is -185%, being 169% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	219,564
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,658
Liabilities, Non-Current	45,084
Other Assets	7,171
Other Compr. Net Income	-183
Other Expenses	0
Other Liabilities	0
Other Net Income	1,569
Property and Equipment	37,002
Research and Development	100,392
Revenues	2,702
Selling, General and Administrative Expense	32,573

Output Variable	Value in 1000 USD
Assets	263,737
Liabilities	67,742
Expenses	132,965
Stockholders Equity	195,995
Net Income	-128,694
Comprehensive Net Income	-128,786
Economic Capital Ratio	-185%

